TANDEM DIABETES CARE INC (TNDM) — SEC Filings

Latest SEC filings for TANDEM DIABETES CARE INC (TNDM), explained in plain English.

Sentiment Overview: 1 bullish, 1 bearish, 28 neutral, 1 mixed

Recent Filings (31)

• Tandem Diabetes Care Files 8-K with Corporate Updates — 8-K · 2025-12-30T00:00:00.000Z [neutral] Risk: low
  Tandem Diabetes Care, Inc. filed an 8-K on December 30, 2025, reporting events as of December 26, 2025. The filing primarily concerns amendments to its Articles
• 8-K Filing — 8-K · 2025-11-12T00:00:00.000Z [neutral]
• 8-K Filing — 8-K · 2025-11-06T00:00:00.000Z [neutral]
• Tandem Diabetes Care Files 8-K — 8-K · 2025-08-07T00:00:00.000Z [neutral] Risk: low
  On August 6, 2025, Tandem Diabetes Care, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific details re
• Tandem Diabetes Narrows Q2 Loss on Strong Revenue Growth — 10-Q · 2025-08-06T00:00:00.000Z [mixed] Risk: medium
  Tandem Diabetes Care Inc. reported a net loss of $10.5 million for the three months ended June 30, 2025, a significant improvement from the net loss of $25.1 mi
• Tandem Diabetes Care Files 8-K on Agreements and Shareholder Votes — 8-K · 2025-05-23T00:00:00.000Z [neutral] Risk: medium
  On May 21, 2025, Tandem Diabetes Care, Inc. filed an 8-K report detailing two key events. The company entered into a Material Definitive Agreement and submitted
• Tandem Diabetes Care Files 8-K Report — 8-K · 2025-05-20T00:00:00.000Z [neutral] Risk: low
  On May 16, 2025, Tandem Diabetes Care, Inc. filed an 8-K report to disclose other events. The filing does not contain specific details about the nature of these
• Tandem Diabetes Care Files 8-K Report — 8-K · 2025-05-12T00:00:00.000Z [neutral] Risk: low
  On May 9, 2025, Tandem Diabetes Care, Inc. filed an 8-K report. The filing primarily concerns the company's current status and does not disclose specific new ma
• Tandem Diabetes Care Q1 2025 10-Q Filing — 10-Q · 2025-04-30T00:00:00.000Z [neutral] Risk: medium
  Tandem Diabetes Care, Inc. filed its quarterly report for the period ending March 31, 2025. The company, headquartered in San Diego, CA, is involved in the surg
• Tandem Diabetes Care Files 2025 Proxy Statement — DEF 14A · 2025-04-08T00:00:00.000Z [neutral] Risk: medium
  Tandem Diabetes Care Inc. filed its DEF 14A proxy statement on April 8, 2025, for the fiscal year ending December 31, 2024. The filing details executive compens
• Tandem Diabetes Care Files 2024 10-K — 10-K · 2025-02-26T00:00:00.000Z [neutral] Risk: medium
  Tandem Diabetes Care Inc. filed its 2024 10-K on February 26, 2025, reporting on its fiscal year ending December 31, 2024. The company, based in San Diego, CA,
• SC 13G/A Filing — SC 13G/A · 2024-11-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-11-08T00:00:00.000Z [neutral]
• Tandem Diabetes Care Files Q3 2024 10-Q — 10-Q · 2024-11-06T00:00:00.000Z [neutral] Risk: medium
  Tandem Diabetes Care, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the thi
• SC 13G/A Filing — SC 13G/A · 2024-10-18T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-09-09T00:00:00.000Z [neutral]
• Tandem Diabetes Care Q2 2024 10-Q Filed — 10-Q · 2024-08-01T00:00:00.000Z [neutral] Risk: medium
  Tandem Diabetes Care, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the second q
• Tandem Diabetes Care Announces Executive and Board Changes — 8-K · 2024-06-21T00:00:00.000Z [neutral] Risk: medium
  On June 19, 2024, Tandem Diabetes Care, Inc. announced changes in its executive team and board of directors. The company appointed new officers and elected new
• Tandem Diabetes Care Enters Material Definitive Agreement — 8-K · 2024-06-18T00:00:00.000Z [neutral] Risk: medium
  On May 22, 2024, Tandem Diabetes Care, Inc. entered into a material definitive agreement. The filing does not disclose specific details of the agreement, such a
• Tandem Diabetes Care Announces Director Changes and Shareholder Votes — 8-K · 2024-05-23T00:00:00.000Z [neutral] Risk: low
  Tandem Diabetes Care, Inc. announced on May 22, 2024, the departure of director Dr. Steven R. Smith and the election of Dr. Jennifer L. Schneider as a new direc
• Tandem Diabetes Care Files 8-K — 8-K · 2024-05-16T00:00:00.000Z [neutral] Risk: low
  On May 10, 2024, Tandem Diabetes Care, Inc. entered into a Material Definitive Agreement. The filing also includes other events and financial statements/exhibit
• Tandem Diabetes Care Q1 2024 Financial Update — 10-Q · 2024-05-02T00:00:00.000Z [neutral] Risk: medium
  Tandem Diabetes Care Inc. reported its first quarter 2024 results, ending March 31, 2024. The company's financial statements show changes in common stock, addit
• Tandem Diabetes Care Executive Compensation Revealed — DEF 14A · 2024-04-09T00:00:00.000Z [neutral] Risk: medium
  Tandem Diabetes Care Inc. filed its DEF 14A on April 9, 2024, detailing executive compensation for the fiscal year ending December 31, 2023. The filing includes
• Tandem Diabetes Care Files 8-K — 8-K · 2024-04-01T00:00:00.000Z [neutral] Risk: low
  On March 21, 2024, Tandem Diabetes Care, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material ev
• Tandem Diabetes Care Files 8-K on Financing and Equity — 8-K · 2024-03-11T00:00:00.000Z [neutral] Risk: medium
  On March 4, 2024, Tandem Diabetes Care, Inc. entered into a Material Definitive Agreement related to its financing. The company also reported on the creation of
• Tandem Diabetes Care Reports Widened Net Loss in 2023 — 10-K · 2024-02-21T00:00:00.000Z [bearish] Risk: high
  Tandem Diabetes Care Inc. reported a net loss of $122.9 million for the fiscal year ended December 31, 2023, compared to a net loss of $13.7 million in 2022. Th
• SC 13G Filing — SC 13G · 2024-02-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral]
• Capital World Investors Amends Tandem Diabetes Stake to 9.9% — SC 13G/A · 2024-02-09T00:00:00.000Z [neutral] Risk: low
  Capital World Investors, a major institutional investor, has updated its holdings in Tandem Diabetes Care Inc. As of December 29, 2023, they beneficially own 6,
• FMR LLC & Abigail Johnson Trim Tandem Diabetes Stake to 4.565% — SC 13G/A · 2024-02-09T00:00:00.000Z [neutral] Risk: low
  FMR LLC, a major investment firm, and its principal owner, Abigail P. Johnson, have updated their ownership stake in Tandem Diabetes Care Inc. As of December 31
• BlackRock Maintains 15.6% Stake in Tandem Diabetes Care (TNDM) — SC 13G/A · 2024-01-23T00:00:00.000Z [bullish]
  BlackRock Inc. has updated its ownership stake in Tandem Diabetes Care Inc. (TNDM) as of December 31, 2023, filing an amendment to its Schedule 13G. This filing